| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1655 | D2r Agonist Rel-trans-16b | Novel potent and selective agonist of dopamine D 2 receptor (D 2 R; K i = 4.58 nM) |
|
| DCC1656 | D3r Agonist Rel-cis-14a | Novel potent and selective agonist of dopamine D 3 receptor (D 3 R; Ki = 5.72 nM) |
|
| DCC1657 | D483-1785 | Novel ERK2 inhibitor |
|
| DCC1658 | D561-0775 | Novel direct AMPK agonist, showing potential anti-cancer activity via inducing apoptosis, cell cycle arrest, suppressing glycolysis and cholesterol synthesis after activation of AMPK in gefitinib-resistant H1975 cells |
|
| DCC1659 | D-87503 | Novel dual extracellular signaling-related kinase (ERK)/PI3K inhibitor |
|
| DCC1660 | Da-6886 | Novel 5-HT4 receptor agonist to accelerate colonic motor activity in mice |
|
| DCC1661 | Daam-3 | Novel inhibitor of SET7/9 |
|
| DCC1662 | Dab-boro-nle | Novel selective and potent DPP7 inhibitor with a DPP7 IC50 value of 480 pM |
|
| DCC1663 | Dab-pip Bis-tfa Salt | Selective inhibitor of human DPP7 |
|
| DCC1664 | Daf-2-da | Widely used fluorescent detector of nitric oxide in culture medium, tissue sections and biopsy cells |
|
| DCC1665 | Dan004 | Novel potent Bax inhibitor, showing concentration-dependent inhibition of liposome permeabilization with improved activity in vitro |
|
| DCC1666 | Danicalipin A | Lipid bilayer modulator which likely inserts into lipid bilayers in the headgroup region, alters their structure and phase behavior, thins the bilayer and fluidizes it, allowing even saturated lipid to form fluid bilayers |
|
| DCC1667 | Dansyl-neca | Potent and selective fluorescent adenosine A1 receptor agonist |
|
| DCC1668 | Dapl-in-1 | Novel inhibitor of L,L-diaminopimelate aminotransferase (DapL) |
|
| DCC1669 | Dapoxetine | Potent Selective serotonin reuptake inhibitor (SSRI) |
|
| DCC1670 | Darapladib-impurity | An impurity formed in Darapladib production |
|
| DCC1671 | Das-6-2-2-6-crbn | Proteolysis targeting chimeras (PROTAC), acting as a degrader of oncogenic BCR-ABL |
|
| DCC1672 | Das-6-2-2-6-vhl | Proteolysis targeting chimeras (PROTAC), acting as a degrader of oncogenic BCR-ABL |
|
| DCC1673 | Das-iap | Novel PROTAC targeting drug-resistant BCR-ABL |
|
| DCC1674 | Dasiglucagon | Novel glucagon analog for diabetic hypoglycemia therapy |
|
| DCC1675 | Dasolampanel Etibutil | Novel selective ionotropic glutamate receptor 5 (iGluR5) antagonist |
|
| DCC1676 | Daw-22 | Biological Active Reagents |
|
| DCC1677 | Db07107 | Novel tyrosine kinase inhibitor for drug resistant T315I mutant BCR-ABL |
|
| DCC1678 | Db1255 | Novel ERG/DNA binding inhibitor, targeting the DNA-binding activity of the human ERG transcription factor |
|
| DCC1679 | Db1960 | Novel antileishmanial agent, against both intracellular Leishmania donovani and intracellular Leishmania amazonensis and displaying dose-dependent reduction of liver parasitemia |
|
| DCC1680 | Dbco-stco | Novel protein cross-linking agent |
|
| DCC1681 | Dbm-1285 Dihydrochloride | p38 MAPK inhibitor, supressing p38 phosphorylation and LPS-induced TNF-α production in macrophages |
|
| DCC1682 | Dbpr110 | Potent HCV NS5A inhibitor |
|
| DCC1683 | Dc_501 | Novel selective non-nucleoside inhibitor of DNA methyltransferase 1 (DNMT1) |
|
| DCC1684 | Dc_m5_2 | Novel inhibitor of WDR5-MLL1 interaction |
|
